[1] FOLKMAN J.Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186. [2] WANG ZD, YANG J, LI ZF.Tumor anti angiogenesis targeted therapy[J]. Chinese Journal of Practical Surgery(中国实用外科杂志), 2010,30(7): 613-615. [3] MENG JX, WANG X, CAO YP, et al.Research progress of drugs targeting anti-tumor blood vessels[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2016, 32(10): 956-960. [4] GRESSETT SM,SHAH SR.Intricacies of bevacizumab-induced toxicities and their management[J]. Ann Pharmacother, 2009, 43(3): 490-501. [5] LI BY, GUO DH, KONG XH, et al.Analysis of 972 spontaneous reports of adverse reactions of anti-tumor angiogenesis drugs[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2021, 37(11): 1441-1443, 1450. [6] YAO C, LIU DJ, GUO DH, et al.Research and development of active monitoring and evaluation warning system II for clinical adverse drug events[J]. China Drug Application and Monitoring(中国药物应用与监测), 2020, 17(6): 380-385. [7] Editorial Department of This Journal. Article recommendation of China cancer clinic: expert diagnosis and treatment consensus of cancer chemotherapy-related thrombocytopenia in China (2019 Edition)[J]. China Cancer Clinic(中国肿瘤临床), 2020, 47(2): 108. [8] ZHANG C, QU RN, MIAO W, et al.Rationality and safety evaluation of bevacizumab in clinical application[J]. Chinese Journal of New Drugs(中国新药杂志), 2017, 26(17): 2107-2112. [9] ZHENG DY, ZHAI SY, CUI R, et al.Analysis of 4 120 cases of adverse reactions of antitumor drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2014, 11(5): 291-294. [10] LI R, Zhao BQ, ZHANG YH.Analysis of adverse reactions of bevacizumab in the treatment of malignant tumors[J]. Chinese Journal of New Drugs(中国新药杂志), 2013, 22(17): 2097-2102. [11] QIU L, LIU Y, HOU LW, et al.Retrospective analysis of adverse reactions associated with bevacizumab in the treatment of malignant tumors[J]. Journal of Pharmacoepidemiology(药物流行病学杂志), 2019,28(2): 118-121. [12] CRIN L, DANSIN E, GARRIDO P, et al.Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study[J]. Lancet Oncology, 2010, 11(8): 733-740. [13] SANDLER A, GRAY R, PERRY MC, et al.Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[J]. The New England Journal of Medicine,2006,355(24): 2542-2550. [14] JOHNSON DH, FEHRENBACHER L, NOVOTNY WF, et al.Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2004, 22(11): 2184-2191. [15] TSAI C, GRIESINGER F, LASKIN J, et al.9171 Low incidence of grade 3 bleeding events and low discontinuation rates associated with first-line bevacizumab (Bev) in patients with advanced NSCLC: data from the SAiL (MO19390) study[J]. EJC Supplements,2009, 7(2): 557-558. [16] ZHANG H, GAO LL, LI ZX, et al.Clinical analysis of chemotherapy on bone marrow suppression in breast cancer patients[J]. China Modern General Surgery Progress(中国现代普通外科进展), 2010,13(8): 630-632. [17] CHANG YY, ZHU B.Establishment of risk prediction scoring system for thrombocytopenia caused by XELOX chemotherapy in patients with gastric cancer[J]. Chinese Journal of Clinical Pharmacy(中国临床药学杂志), 2019,28(6): 414-418. [18] XU XY, ZHU XQ, LIU XJ.Influencing factors of severe bone marrow suppression after TC regimen chemotherapy in patients with gynecological malignant tumors[J]. Journal of Zhengzhou University (Medical Edition)(郑州大学学报医学版), 2016, 51(5): 657-660. [19] WU XW, HUANG YH, QIU CF.Exploring the risk factors and prediction methods of bone marrow suppression in non-small cell lung cancer based on logistic regression analysis[J]. Anhui Medicine(安徽医药), 2021, 25(5): 894-898. [20] SHI YF, CHEN W, CAO Y, et al.Analysis of influencing factors of bone marrow suppression in patients with non-small cell lung cancer after chemotherapy[J]. Journal of Clinical Drug Therapy(临床药物治疗杂志), 2019, 17(11): 38-43, 61. [21] RACANELLI AC, ROTHBART SB, HEYER CL, et al.Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition[J]. Cancer Res, 2009, 69(13): 5467-5474. [22] CHEN J, WEI S, LI X.Critical appraisal of pemetrexed in the treatment of NSCLC and metastatic pulmonary nodules[J]. Onco Targets and Therapy, 2014(7): 937-945 [23] ZINNER R, VISSEREN-GRUL C, SPIGEL D, et al.Pemetrexed clinical studies in performance status 2 patients with non-smallcell lung cancer (Review)[J]. International Journal of Oncology, 2016, 48(1): 13-27. [24] MA L, SHI JF, TONG N.Study on adverse reactions of Paclitaxels[J]. China Pharmacy(中国药房), 2018, 29(21): 3014-3017. [25] XIE S, WEI CS.Investigation and analysis of bone marrow suppression in tumor chemotherapy patients[J]. China Modern Applied Pharmacy(中国现代应用药学), 2010,27(S1): 1219-1221. [26] ZHU Q, XU LH.Analysis of related factors of bone marrow suppression caused by antitumor drugs[J]. Pharmaceutical and Clinical Research(药学与临床研究), 2015, 23(1): 68-70. [27] HU PZ, GUO DH, JIA WP, et al.Study on intelligent real-time monitoring of adverse drug reactions related to cinepazide maleate injection[J]. China Drug Application and Monitoring(中国药物应用与监测), 2018, 15(2): 92-95. [28] YANG H, GUO D, JIA W, et al.Incidence, clinical features, and risk factors of fluoroquinolone-induced acute liver injury: a case-control study[J]. Ther Clin Risk Manag, 2019, 15: 389-395. [29] SU L, HUO H, LIU GX, et al.Application analysis and rationality evaluation of bevacizumab[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2017, 37(9): 855-858. |